Strong Financial Performance#
Medacta, a Switzerland-based medical device company, recently released its full fiscal year 2025 results. The company reported an adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of €191 million, which was about 1% higher than analysts' expectations. This positive outcome was achieved despite challenges from foreign exchange fluctuations, which affected gross profit margins.
Key Financial Metrics#
The adjusted EBITDA margin for the full year was 27.9%, or 29% when adjusted for constant currencies. Reported EBITDA, which includes the impact of the Parcus acquisition, reached €201.5 million. Medacta also showcased impressive cash flow performance, with operating cash flow increasing by 42.5% to €152.7 million. Free cash flow improved to €15.7 million, up from €8.3 million in the previous year, although it was limited by capital expenditures totaling €137 million.
Investment in Growth#
Approximately 80% of Medacta's capital expenditures were allocated to growth initiatives. This included €78.2 million for surgical instruments and the expansion of production facilities, indicating the company's commitment to enhancing its product offerings and operational capabilities.
Updated Growth Guidance#
Looking ahead, Medacta has issued guidance for fiscal year 2026, projecting growth between 10% and 14% in constant currencies. Additionally, the company has upgraded its midterm growth forecast to a range of 12% to 15%, up from the previous 10% to 14%. This guidance also anticipates a slight expansion in the adjusted EBITDA margin by 50 basis points from the current level of approximately 27.9%. Furthermore, Medacta announced a dividend that exceeded analyst expectations by 12%.
Medacta specializes in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices, including products for hip, knee, shoulder, and spine surgeries. The Siccardi family retains a 70% ownership stake in the company.